Creating a new generation of small molecule protease inhibitors

Investors Overview

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

NASDAQ | KALV (Common Stock)
$7.00+0.08 (1.16%)
Stock chart for: KALV.O. Currently trading at $7.00 with a 52 week high of $10.65 and a 52 week low of $5.48.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources

Recent News

September 14, 2017KalVista Pharmaceuticals Reports Fiscal First Quarter Results

August 08, 2017KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

July 27, 2017KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results

More News

Upcoming Events

There are currently no events scheduled.

More Events

Featured Presentations

Download Documentation Wedbush PacGrow Healthcare Conference Presentation